BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shed $7.92 (66%) to $4.02 on Tuesday after its mesenchymal stem cell therapy NurOwn missed the primary endpoint in a...
BioCentury | Sep 26, 2016
Company News

Institut National de la Sante et de la Recherche Medicale, Evotec deal

...Transfert subsidiary to characterize and develop selective modulators of Ras homolog gene family member B (RHOB...
BioCentury | Sep 18, 2014
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Ras homolog family member T1 (Rhot1; Miro1)-deficient mouse models of motor neuron disease Miro1-deficient mice could be useful as models of motor neuron diseases. Miro1...
BioCentury | Feb 13, 2014
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ras homolog family member J (RHOJ) Studies in mice suggest antagonizing RHOJ could help treat cancer by disrupting the tumor...
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Respiratory distress syndrome (RDS) Ras homolog family member A (RHOA) Cell culture and mouse studies suggest blocking nitration of RHOA could help treat acute...
Items per page:
1 - 5 of 5